Epidemiology of Cervical Cancer.
10.5124/jkma.2007.50.9.762
- Author:
Kyu Wan LEE
1
;
Jae Yun SONG
Author Information
1. Department of Obstetrics and Gynecology, Korea University College of Medicine, Korea. pumplee@kumc.or.kr, yuni105@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Epidemiology;
Cervical cancer;
Incidence;
Human papillomavirus
- MeSH:
Adenocarcinoma;
Africa South of the Sahara;
Asia;
Carcinoma, Squamous Cell;
Caribbean Region;
Developing Countries;
Epidemiologic Studies;
Epidemiology*;
Europe;
Far East;
Female;
Humans;
Incidence;
Korea;
Latin America;
Mass Screening;
Melanesia;
Middle Aged;
North America;
Parity;
Survival Rate;
Uterine Cervical Neoplasms*
- From:Journal of the Korean Medical Association
2007;50(9):762-768
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Invasive cancer of the cervix is considered a preventable disease because it has a long preinvasive state, cervical cytology screening programs are currently available, and the treatment of pre-invasive lesions is effective. Cancer of the cervix is the second most common cancer among women worldwide, with an estimated 493,000 new cases and 274,000 deaths in 2002. The highest incidence rates are observed in sub-Saharan Africa, Melanesia, Latin America and the Caribbean, South-Central Asia, and South East Asia. In Korea, cervical cancer is the fifth most common cancer among women with over 3,000 new cases every year. Age-standardized incidence rate (ASR) is 15.5 per 100,000, which is lower than those in developing countries but higher than in western countries such as Europe and North America. The patients' mean parity is 2.59, and the range of age in peak incidence is 40~49 years (29.8%), followed by 50~59 years (21.9%). As the age goes on, more advanced stage cancer is frequent. Squamous cell carcinoma is the most common cell type, and adenocarcinoma is more frequent among those under 60 years old. Operation (56.0%) is the major treatment modality under stage IIa, and concurrent chemoradiation (31.6%) is the major treatment over stage IIb. The 5year survival rate is 73.9%. It is generally thought that human papillomavirus (HPV) test and HPV vaccine might play an important role in lowering the incidence of cervical cancer, and continuous epidemiologic studies will support its usefulness and efficacy.
